WuXi Biologics is a leading contract research, development and manufacturing organization (CRDMO) that provides end-to-end capabilities to healthcare organizations worldwide. With operations in China, the United States, Ireland, Germany, and Singapore, we enable our partners to effectively and efficiently bring biologics and vaccines to patients worldwide through our comprehensive and high-quality drug development model.

WuXi XDC （ 2268.HK ） is a leading global CRDMO focused on antibody drug conjugates (ADC) and the broader bioconjugate market. It provides end-to-end contract research, development and manufacturing services for bioconjugates, including ADCs. Its services cover antibody intermediates and other biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products.

Merck, a leading science and technology company, operates across life science, healthcare and electronics. To the life science industry, we provide solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production. The Millipore® portfolio of Merck offers an ecosystem of industry-leading products and services, spanning preparation, separation, filtration and monitoring, as well as clinical and commercial biomanufacturing CTDMO services - all of which are deeply rooted in quality, reliability and time-tested processes. The SAFC® portfolio of Merck offers customized and ready-to-use raw material solutions, backed by deep regulatory expertise. Our proven products, expert services and regulatory and application expertise are a strong foundation you can rely on to consistently perform at the highest level.

Evonik is one of the world leaders in the specialty chemicals industry. Active in more than 100 countries around the world, Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. We contribute small amounts of material that make a big difference. We provide the highest quality cell culture media ingredients for biologic drugs development & manufacturing, produce lipid nanoparticles essential in mRNA-based COVID-19 vaccines, make tires more fuel-efficient, and animal feeds healthier. As one of the key growth regions, Evonik has a strong production and R&D footprint in Asia Pacific. With over 5,000 employees at more than 50 production sites, the region contributed to €3.4 billion sales in 2021.